Tenecteplase Clot-Busting Drug Tested in Posterior Circulation Stroke
Tests tenecteplase clot-busting drug in adults with acute posterior circulation ischemic stroke.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset
Key facts
- Where
- Hefei, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07094763, who can take part
Where in China
- The First Affiliated Hospital of the University of Science and Technology of ChinaHefei, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of University of Science and Technology of China
- Trial code
- NCT07094763
- Record updated
- 8 June 2026
- Original description
This study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute posterior circulation ischemic stroke.Read full original descriptionShow less
Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset: A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Trial
This study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute posterior circulation ischemic stroke.
Inclusion: Age ≥18 years; Meeting at least one of the following criteria: acute posterior circulation ischemic stroke confirmed by MRI; symptomatic stenosis or occlusion of a posterior circulation large vessel on vascular imaging (CTA/MRA/DSA); perfusion imaging demonstrating clinically relevant hypoperfusion in the posterior circulation territory; Onset time between 4.5-24 hours (for wake-up stroke or unwitnessed stroke, onset time is defined as the midpoint between last known well and symptom detection); NIHSS score>3; PC-ASPECTS ≥7 (if discrepancy exists between DWI and CT findings, CT assessment takes precedence); Pre-stroke mRS ≤1; Signed informed consent by the patient or legally authorized representative.
Exclusion: Planing to receive endovascular therapy with thrombectomy, angioplasty or stenting whin 3 months; History of intracranial hemorrhage; Stroke, myocardial infarction, severe traumatic brain injury, or intracranial/spinal surgery within the preceding 3 months; Active internal bleeding, major surgery, trauma, gastrointestinal/urinary tract bleeding within 3 weeks; Uncontrolled hypertension (systolic BP >180 mmHg or diastolic BP >110 mmHg unresponsive to antihypertensive therapy); Clinically significant bleeding or coagulopathy, including: Warfarin use with INR >1.7 or PT >15 s; Low-molecular-weight heparin within 24 hours; Direct oral anticoagulants within 48 hours; Laboratory abnormalities (e.g., APTT >40 s); Platelet dysfunction or platelet count <100×10⁹/L; Uncontrolled hypoglycemia/hyperglycemia (<50 mg/dL [2.8 mmol/L] or >400 mg/dL [22.2 mmol/L]); Contraindication to tenecteplase or its components; Acute anterior circulation infarction confirmed by MRI, anterior circulation large vessel occlusion on vascular imaging (CTA/MRA/DSA), or anterior circulation hypoperfusion on perfusion imaging; Intracranial tumor, arteriovenous malformation (AVM), or giant aneurysm; Non-compressible arterial puncture within 1 week; Suspected aortic dissection; Pregnancy or lactation; A life expectancy of less than three months; Participation in other clinical trials within 3 months or ongoing trial enrollment; Inability to follow up (e.g., no fixed residence, overseas patients); Patient deemed unsuitable for the trial by site investigator.